Podcast 34: Parenteral Drugs: CDMOs/CMOs Expanding

Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand.

Key topics: (see Chapter Markers in drop down menu in audio player above)

  • Active area of investment (1:13)
  • Baxter BioPharma Solutions (1:25)
  • PCI Pharma Services (2:07)
  • Alcami (3:22)
  • Catalent (4:31)
  • Vetter (5:47)
  • Thermo Fisher Scientific (6:41)
  • Grand River Aseptic Manufacturing (7:35)
  • Lonza (9:12)
  • Curia (9:50)
  • Jubilant HollisterStier (10:22)
  • Carbogen Amcis (10:53)
  • Fareva (11:46)
  • BSP Pharmaceuticals (12:43)
  • Recipharm (13:33)
  • Aenova (15:01)
  • Wuxi Biologics (15:42)
  • Samsung Biologics (16:08)
  • Ajinomoto Bio-Pharma Services (16:44)
  • Selkirk Pharma (17:07)

Sponsor: Vetter Pharma International GmbH

Links:
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)